The Global "Fertility Testing Devices Market" is expected to grow at a high CAGR during the forecasting period (2022-2029).
Fertility testing is the process in which the fertility of an individual is been assessed. These tests can be performed in general or to find out the fertile window. Fertility testing is undertaken by both men and women, for the assessment of their fertility and various conditions associated with it. Both men and women experience fertility problems at equal rates, but women are considered to be more concerned about fertility testing.
The global fertility testing devices market growth is driven by the rise in the prevalence of diseases such as Polycystic Ovary Syndrome (PCOS) as women with the condition of PCOS do not ovulate each month regularly due to the overproduction of estrogen by the ovaries. An increase in first-time pregnancies among women and declining fertility rates across the globe also drive market growth.
Technological advancements and the availability of home-based fertility kits will drive the market growth
Earlier, the testing procedures included manual lab-based testing and computer-assisted semen analysis systems that were time taking as well as expensive. To combat such issues, companies manufacturing fertility testing devices are focusing on the development of advanced testing kits that are smartphone-based and provide rapid results. For instance, in March 2017, scientists from Massachusetts General Hospital (MGH) developed a smartphone-based semen analyzer for fertility testing in men. This testing kit is easy to use, inexpensive, and fully automated. Also, in 2018, Brigham and Women’s Hospital in Massachusetts developed a cost-effective smartphone application that can predict a woman’s ovulation cycle. The testing kit is made using microfluidic technology, and artificial intelligence (AI). This device automatically detects fern-like patterns from saliva samples which is a marker of ovulation.
Moreover, the launch of technologically advanced products and changes in lifestyle can result in increased growth of the fertility testing devices market. For instance, in June 2020, Modern Fertility launched the pregnancy and ovulation test kit. The company also launched a special app for it to centralize all fertility-related data. The app helps in reading and tracking the test results, which is a broader push by the company to shift the fertility category into mainstream wellness. Similarly, in March 2020, Proov received approval from the Food and Drug Administration (FDA) for its product at-home ovulation testing kit. This kit tests the presence of PdG, a urine metabolite of progesterone, which is a hormone released by the woman’s ovary after ovulation. In May 2019, Fertility Focus Limited launched the updated version of the OvuSense app (OvuSense V.2.). It features increased flexibility in data viewing and increased accuracy.
Lack of regulation guidelines and malfunctioning devices will hamper the market growth
The market is hugely dependent on the monitoring devices and the test kits, however, lack of regulation guidelines, malfunctioning of the devices, and also the price fluctuations are the major concern for the fertility testing devices market.
The pandemic has had mixed effects on the fertility testing devices market. On one hand, due to the luxury of time offered by the lockdowns, many couples planned for a conception during the pandemic. On the other hand, many organizations estimate that the economic crisis during COVID-19, as well as the resulting unemployment, a surge in domestic violence, and restricted access to healthcare during the antenatal period, will affect birth rates, resulting in fewer million babies.
Organizations that deal with reproductive health are recommending, out of caution and concern for the lack of data (regarding the relationship between pregnancy and COVID-19), that couples planning pregnancies should hold off for the time being. The European Society of Human Reproduction and Embryology states that all fertility patients considering or planning treatment, even if they do not meet the diagnostic criteria for COVID-19 infection, should avoid becoming pregnant at this time.
The ovulation prediction kits segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The ovulation prediction kits are used to detect the exact day of ovulation for a woman who is planning for a conception. There are many kinds of ovulation prediction kits on the market. Most of the kits work by measuring the luteinizing hormone (LH) in the urine. LH levels rise 24-36 hours before ovulation. The high level of LH indicates that the release of the egg (ovulation) usually occurs 12-24 hours after the test turns positive.
According to the Centers for Disease Control, one in eight couples has trouble conceiving or sustaining a pregnancy, due to age, health issues, or other factors. This indicates that there is a need in the market for cost-efficient and accurate ovulation monitors. As ovulation prediction kits provide cost-effective fertility testing, their demand is increasing.
The North American region holds the largest market share of the global fertility testing devices market
North America dominates the global fertility testing devices market. The prevalence of infertility and associated disorders, such as obesity, are on the rise. According to a CDC report, the general fertility rate in the U.S. in 2020 was 56 births per 1000 women. It was nearly half of what it was in the 1960s. Besides infertility issues, increasing adolescent pregnancy in the region is also driving the industry’s expansion. In June 2021, the Brookings Institution estimated that in the United States, the public health crisis and associated recession will result in 300,000 to 500,000 fewer births in 2021. According to the Guttmacher Institute survey, 2020, 34% of American women have either delayed their plans to have a child or reduced the number of children they expect to have because of the pandemic.
In 2018, the United States experienced a record low fertility rate. The fertility rate in the United States in 2018 was 1.776 births per woman, a 1.11% decline from 2017 (1.796). The number of births in the country dropped by 2% between 2016 and 2017, to 60.2 births per 1,000 women aged 15-44 years, continuing a general downward trend that started with the Great Recession of 2008. This marks the lowest that the fertility rate of the country has been in 30 years. According to the National Center for Health Statistics (2017), birth rates declined to record lows among all groups under the age of 30. Among women aged 20-24 years, the decline was 4%, whereas, for women aged 25-29 years, the rate fell to 2%. Hence, the decreasing fertility rates and rising awareness about fertility testing are driving the fertility testing device market in the region.
The fertility testing devices market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Church & Dwight Co. Inc. Fairhaven Health LLC, Fertility Focus Limited, Uebe Medical GmbH, HiLin Life Products Inc., Prestige Brands Holdings Inc., Quidel Corporation, Swiss Precision Diagnostics GmbH, Advocar Pharma, Babystart among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the fertility testing devices market globally. For instance, in June 2020, Modern Fertility launched pregnancy and ovulation tests, along with a mobile application to centralize all fertility-related data.
Quidel Corporation is a provider of rapid diagnostic testing solutions, cellular-based virology assays, and molecular diagnostic systems. The Company is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions.
QuickVue hCG Urine Test: The QuickVue hCG Urine Test is a sensitive immunoassay that detects human chorionic gonadotropin (hCG) in urine for the early detection of pregnancy.
Get your free sample proposal with a single click!